Press Release Date: September 16, 2014
ESNano has achieved a successful demonstration of the potential real world applications in the treatment of Type 2 diabetes mellitus with the binding of glucagon like peptides (GLP-1) to our proprietary GNS in our recently completed Pre-Clinical trial process.
The possibilities offered by the binding of GLP-1 molecules to ESNano’s industry leading golden nano-spheres technology had from even the earliest stages of the Pre-Clinical trial process shown some promising results for concept in clinical applications and because of this our process has already seen industry wide interest for many obvious as well as some more subtle reasons.
Currently the worldwide market for glucagon like peptides in the treatment of Type 2 diabetes mellitus stands at around $4 billion dollars per annum and improving the efficiency of this treatment regime has been at the center of great research efforts across the industry over the last five years. ESNano’s demonstrating the capacity of successful binding of GLP-1 molecules with the barrier penetrating efficiency of our proprietary golden nano-spheres has shown that we are at the very head of the race in delivering a viable solution.
Type 2 Diabetes Mellitus, often referred to as Adult Onset diabetes is the leading diabetic condition in the world with some 285 million people afflicted with the condition around 90% of all diabetes cases as of a W.H.O survey released in 2010. This number of sufferers being equivalent to nearly 6% of the adult population of the world with cases common to both developed and developing nations as life style factors begin to become more similar in nature.
“Glucagon like peptides are just some of the prescribed treatment methods that comprise the backbone of our current response to conditions associated with Type 2 diabetes mellitus, but actual efficiency of treatment has been viewed as a rather unpredictable affair, a situation that we are endeavoring to rectify by showing that in combination with our golden nano-sphere technology we will be able to significantly better the outcomes of success while lowering overall treatment costs.” remarked Dr. Eli Stein, ESNano Technology Development Ltd’s COO, CMO while discussing the results of the trial process.
Go Back to Press Articles